Status
Conditions
Treatments
About
This study is a prospective, multicenter, randomized (1:1) controlled comparative effectiveness trial of a transseptal approach to left ventricular ablation compared to a retrograde aortic approach to prevent cerebral emboli and neurocognitive decline in adults with ventricular tachycardia (VT) and/or premature ventricular contractions (PVCs).
Full description
This study is a prospective, multicenter, randomized (1:1) controlled comparative effectiveness trial of a transseptal approach to left ventricular ablation compared to a retrograde aortic approach to prevent cerebral emboli and neurocognitive decline in adults with ventricular tachycardia (VT) and/or premature ventricular contractions (PVCs). Participants will be followed for 6 months post-study procedure. This study will be conducted at up to 12 clinical sites in the United States. A total of one-hundred and fifty (150) participants will be enrolled and randomized.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Planned epicardial ablation that would include a coronary angiogram (during the index ventricular tachycardia (VT) or premature ventricular contraction (PVC) catheter ablation procedure)
Any contraindication to MRI (as defined by the institution performing the MRI)
Clinical contraindication to a retrograde aortic approach as determined by the treating physician, including:
Clinical contraindication to a transseptal puncture as determined by the treating physician, including:
Planned or known need to perform either a retrograde aortic approach or transseptal approach (such as to target another site during the same procedure)
Inability to speak, read, and write in the English language at a 6th grade level (required for the Neurocognitive Function Testing)
Current mental impairment or other diagnosis which precludes accurate assessment of neurocognitive function or which may not allow patient to understand the nature, significance and scope of the study
Inability to perform neurocognitive function testing after > 24 hours free of sedating medications
Primary purpose
Allocation
Interventional model
Masking
153 participants in 2 patient groups
Loading...
Central trial contact
Trisha F. Hue, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal